Table 1.
Patient characteristics.
| Detection indexes | Patients (n = 190) |
|---|---|
| Age, y | 53.21 ± 7.38 |
| Male, n (%) | 104 (54.73) |
| Currently smoking, n (%) | 9 (4.73) |
| BMI (kg/m2) | 24.33 ± 2.57 |
| SBP (mmHg) | 156.38 ± 11.36 |
| DBP (mmHg) | 99.55 ± 9.71 |
| HR (bpm) | 94.33 ± 5.63 |
| Comorbidities, n (%) | |
| Respiratory diseases | 2 (1.05) |
| Diabetes | 7 (3.68) |
| Cerebrovascular disease | 5 (2.63) |
| Renal insufficiency | 4 (2.11) |
| Dyslipidemia | 5 (2.63) |
| Medications, n (%) | |
| ACEIs/ARBs | 126 (66.32) |
| Beta-blockers | 163 (85.79) |
| Calcium-channel blockers | 133 (70.00) |
| Diuretics | 190 (100.00) |
| Amiodarone | 32 (16.84) |
| Propafenone | 10 (5.26) |
| Warfarin | 21 (11.05) |
| NOACs | 145 (76.32) |
BMI: body mass index. Respiratory diseases include chronic bronchitis, emphysema, chronic obstructive pulmonary disease, asthma, and moderate and severe pulmonary hypertension. Cerebrovascular disease is defined as a history of stroke, cerebral hemorrhage, carotid artery stent, or angioplasty. Renal insufficiency is defined as serum creatinine eGFR <60 mL/min/1.73 m2. Dyslipidemia is defined as previous dyslipidemia or a history of anti-lipid medication. ACEIs/ARBs: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers; NOACs: novel oral anticoagulants.